Imaging prostate cancer lymph node metastases with a multimodality contrast agent

Prostate

Volumn 72, Issue 2, 2012, Pages 129-146

  Hall, Mary A ^a   Kwon, Sunkuk ^a   Robinson, Holly ^a   Lachance, Pier Anne ^a   Azhdarinia, Ali ^a   Ranganathan, Ranjani ^a   Price, Roger E ^b   Chan, Wenyaw ^c   Sevick Muraca, Eva M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antibody; epithelial cell adhesion molecule; lymph node; near infrared; positron emission tomography computed tomography; prostate cancer

Indexed keywords

COPPER 64; EPITHELIAL CELL ADHESION MOLECULE; MAB 9601 ANTIBODY; TETRAXETAN; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER TRANSPLANTATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONJUGATION; DIAGNOSTIC IMAGING; DRUG TARGETING; EARLY DIAGNOSIS; EX VIVO STUDY; FLUORESCENCE IMAGING; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LYMPH NODE METASTASIS; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEAR INFRARED REFLECTANCE SPECTROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SYNTHESIS;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CONTRAST MEDIA; COPPER RADIOISOTOPES; DISEASE MODELS, ANIMAL; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDOLES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84455203881     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21413     Document Type: Article

References (72)

1. Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL,. Detection of prostate cancer with MR spectroscopic imaging: An expanded paradigm incorporating polyamines. Radiology 2007; 245 (2): 499-506. (Pubitemid 47612532)
2. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE,. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55 (6): 1251-1265.
3. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR,. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 4: Seminal vesicles and lymph nodes. Mod Pathol 2011; 24 (1): 39-47.
4. Heidenreich A, Ohlmann CH, Polyakov S,. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007; 52 (1): 29-37. (Pubitemid 46803038)
5. Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM,. Lymphedema beyond breast cancer: A systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer 2010; 116 (22): 5138-5149.
6. Pilepich MV, Asbell SO, Mulholland GS, Pajak T,. Surgical staging in carcinoma of the prostate: The RTOG experience. Radiation Therapy Oncology Group. Prostate 1984; 5 (5): 471-476. (Pubitemid 14016039)
7. Musch M, Klevecka V, Roggenbuck U, Kroepfl D,. Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. J Urol 2008; 179 (3): 923-928 (Discussion 928-929).
8. Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, Greenfield S, Litwin MS,. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2010; Nov. 29 [Epub ahead of print].
9. Heidenreich A, Varga Z, Von Knobloch R,. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 2002; 167 (4): 1681-1686. (Pubitemid 34240702)
10. Holl G, Dorn R, Wengenmair H, Weckermann D, Sciuk J,. Validation of sentinel lymph node dissection in prostate cancer: Experience in more than 2,000 patients. Eur J Nucl Med Mol Imaging 2009; 36 (9): 1377-1382.
11. Janetschek G, Jeschke S, Leeb K, Prammer P, Ziegerhofer J, Sega W,. Sentinel lymph node dissection for localized prostate cancer. Actas Urol Esp 2007; 31 (6): 686-692.
12. Giuliano A, Hunt K, Ballman K, Beitsch P, Whitworth P, Blumencranz P, Leitch A, Saha S, McCall L, Morrow M,. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011; 305 (6): 569-575.
13. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
14. Xuan JW, Bygrave M, Valiyeva F, Moussa M, Izawa JI, Bauman GS, Klibanov A, Wang F, Greenberg NM, Fenster A,. Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model. Mol Imaging 2009; 8 (4): 209-220.
15. Cai W, Chen K, He L, Cao Q, Koong A, Chen X,. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007; 34 (6): 850-858. (Pubitemid 46798960)
16. Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG,. N-[N-[(S)-1,3-Dicarboxypropyl] carbamoyl]-4-[18F]fluorobenzyl- L -cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin Cancer Res 2008; 14 (10): 3036-3043.
17. Li ZB, Wu Z, Chen K, Ryu EK, Chen X,. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 2008; 49 (3): 453-461. (Pubitemid 351355212)
18. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS,. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004; 45 (8): 1390-1397. (Pubitemid 47618540)
19. Hong H, Zhang Y, Sun J, Cai W,. Positron emission tomography imaging of prostate cancer. Amino Acids 2010; 39 (1): 11-27.
20. Kularatne SA, Wang K, Santhapuram HK, Low PS,. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 2009; 6 (3): 780-789.
21. Hao G, Zhou J, Guo Y, Long MA, Anthony T, Stanfield J, Hsieh JT, Sun X,. A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection. Amino Acids 2010; Mar 11 [Epub ahead of print].
22. Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG,. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010; 53 (14): 5333-5341.
23. Yang M, Jiang P, Yamamoto N, Li L, Geller J, Moossa AR, Hoffman RM,. Real-time whole-body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein. Prostate 2005; 62 (4): 374-379. (Pubitemid 40224141)
24. Tavri S, Jha P, Meier R, Henning TD, Muller T, Hostetter D, Knopp C, Johansson M, Reinhart V, Boddington S, Sista A, Wels WS, Daldrup-Link HE,. Optical imaging of cellular immunotherapy against prostate cancer. Mol Imaging 2009; 8 (1): 15-26.
25. Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, Pomper MG,. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009; 390 (3): 624-629.
26. Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM,. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res 2008; 14 (22): 7488-7496.
27. Leyton JV, Olafsen T, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, Wu AM,. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel 2009; 22 (3): 209-216.
28. Kularatne SA, Zhou Z, Yang J, Post CB, Low PS,. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharm 2009; 6 (3): 790-800.
29. Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG,. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008; 51 (15): 4504-4517.
30. Chen K, Li ZB, Wang H, Cai W, Chen X,. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 2008; 35 (12): 2235-2244.
31. Cai W, Chen K, Li ZB, Gambhir SS, Chen X,. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 2007; 48 (11): 1862-1870. (Pubitemid 350099333)
32. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, Sevick-Muraca EM,. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007; 48 (9): 1501-1510. (Pubitemid 47397400)
33. Wang W, Ke S, Kwon S, Yallampalli S, Cameron AG, Adams KE, Mawad ME, Sevick-Muraca EM,. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem 2007; 18 (2): 397-402. (Pubitemid 46493510)
34. Houston JP, Ke S, Wang W, Li C, Sevick-Muraca EM,. Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. J Biomed Opt 2005; 10 (5): 054010.
35. Marshall MV, Draney D, Sevick-Muraca EM, Olive DM,. Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol 2010; 12 (6): 583-594.
36. Sevick-Muraca EM, Sharma R, Rasmussen JC, Marshall MV, Wendt JA, Pham HQ, Bonefas E, Houston JP, Sampath L, Adams KE, Blanchard DK, Fisher RE, Chiang SB, Elledge R, Mawad ME,. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: Feasibility study. Radiology 2008; 246 (3): 734-741.
37. Baeuerle PA, Gires O,. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007; 96 (3): 417-423. (Pubitemid 46215211)
38. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG,. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006; 103 (2): 483-488. (Pubitemid 44602156)
39. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA,. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94 (1): 128-135. (Pubitemid 43088552)
40. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Kochli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G,. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004; 86 (3): 207-213. (Pubitemid 39070963)
41. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A, Laimer K, Gastl G, Tzankov A, Spizzo G,. Ep-CAM expression in pancreatic and ampullary carcinomas: Frequency and prognostic relevance. J Clin Pathol 2008; 61 (1): 31-35. (Pubitemid 351158222)
42. Epenetos A, Canti G, Taylor-Papadimitriou J, Curling M, Bodmer W,. Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions. Lancet 1982; 2: 1004-1006. (Pubitemid 12035185)
43. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M,. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450 (7173): 1235-1239.
44. Ntouroupi TG, Ashraf SQ, McGregor SB, Turney BW, Seppo A, Kim Y, Wang X, Kilpatrick MW, Tsipouras P, Tafas T, Bodmer WF,. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008; 99 (5): 789-795.
45. Andratschke M, Gildehaus FJ, Johannson V, Schmitt B, Mack B, Reisbach G, Lang S, Lindhofer H, Zeidler R, Wollenberg B, Luebbers CW,. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody. Anticancer Res 2007; 27 (1A): 431-436. (Pubitemid 46363364)
46. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A, Verde PE, Eisenberger CF, Peiper M, Rehders A, Esch JS, Knoefel WT, Hosch SB,. Ep-CAM expression in squamous cell carcinoma of the esophagus: A potential therapeutic target and prognostic marker. BMC Cancer 2006; 6: 165.
47. Herlyn M, Steplewski Z, Herlyn D, Koprowski H,. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979; 76 (3): 1438-1442. (Pubitemid 9136880)
48. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Hayry P, Koprowski H,. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; 1 (8275): 762-765. (Pubitemid 12192184)
49. Sears HF, Herlyn D, Steplewski Z, Koprowski H,. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 1984; 3 (2): 138-150. (Pubitemid 14114011)
50. Brown J, Rasamoelisolo M, Spearman M, Bosc D, Cizeau J, Entwistle J, MacDonald GC,. Preclinical assessment of an anti-EpCAM immunotoxin: Locoregional delivery provides a safer alternative to systemic administration. Cancer Biother Radiopharm 2009; 24 (4): 477-487.
51. Mukherjee S, Richardson AM, Rodriguez-Canales J, Ylaya K, Erickson HS, Player A, Kawasaki ES, Pinto PA, Choyke PL, Merino MJ, Albert PS, Chuaqui RF, Emmert-Buck MR,. Identification of EpCAM as a molecular target of prostate cancer stroma. Am J Pathol 2009; 175 (6): 2277-2287.
52. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS,. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005; 280 (43): 36529-36540. (Pubitemid 41633927)
53. Cooper MS, Sabbah E, Mather SJ,. Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes. Nat Protoc 2006; 1 (1): 314-317.
54. 3. Cancer Res 2006; 66 (19): 9673-9681. (Pubitemid 44623667)
55. Sampath L, Kwon S, Hall MA, Price RE, Sevick-Muraca EM,. Detection of cancer metastases with a dual-labeled near-infrared/positron emission tomography imaging agent. Transl Oncol 2010; 3 (5): 307-317.
56. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr., Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77-89. (Pubitemid 14091996)
57. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC,. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61 (10): 3882-3885. (Pubitemid 32720945)
58. Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P,. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: The positive impact of adjuvant radiotherapy. Eur Urol 2009; 55 (5): 1003-1011.
59. Ahyai SA, Isbarn H, Karakiewicz PI, Chun FK, Reichert M, Walz J, Steuber T, Jeldres C, Schlomm T, Heinzer H, Salomon G, Budaus L, Perrotte P, Huland H, Graefen M, Haese A,. The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU Int 2010; 105 (5): 636-641.
60. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML,. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178 (3 Pt 1): 864-870 (Discussion 870-861).
61. Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Markl B, Gordijn R, Harzmann R,. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003; 43 (2): 132-136 (Discussion 137).
62. Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M,. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 2007; 13 (4): 1192-1197. (Pubitemid 46424060)
63. Fujisawa M, Miyake H,. Significance of micrometastases in prostate cancer. Surg Oncol 2008; 17 (3): 247-252.
64. 18]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology based study. Eu J Ca 2010; 46: 449-455.
65. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P,. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med 2011; 41 (1): 29-44.
66. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W,. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: A prospective study of 130 patients. Radiology 2010; 254 (3): 925-933.
67. Vintersten K, Monetti C, Gertsenstein M, Zhang P, Laszlo L, Biechele S, Nagy A,. Mouse in red: Red fluorescent protein expression in mouse ES cells, embryos, and adult animals. Genesis 2004; 40 (4): 241-246. (Pubitemid 40110709)
68. Troy T, Jekic-McMullen D, Sambucetti L, Rice B,. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging 2004; 3 (1): 9-23.
69. Heesakkers RA, Jager GJ, Hovels AM, de Hoop B, van den Bosch HC, Raat F, Witjes JA, Mulders PF, van der Kaa CH, Barentsz JO,. Prostate cancer: Detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology 2009; 251 (2): 408-414.
70. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA,. American Cancer Society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J Clin 2010; 60 (2): 70-98.
71. Su B, Hrin R, Harvey BR, Wang YJ, Ernst RE, Hampton RA, Miller MD, Strohl WR, An Z, Montgomery DL,. Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays. J Immunol Methods 2007; 322 (1-2): 94-103. (Pubitemid 46560585)
72. Wang X, Hickey RJ, Malkas LH, Koch MO, Li L, Zhang S, Sandusky GE, Grignon DJ, Eble JN, Cheng L,. Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Prostate 2010; 71 (7): 748-754.